TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of motion sickness~* Currently suffering from migraines with at least 2 episodes during the previous 12 months~* Previous use and tolerance to triptans~Exclusion Criteria:~* Current tobacco user~* History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease~* Family history of early myocardial infarction (first-degree relative \< 45 years old at time of event)~* Constant dizziness or constant vestibular symptoms~* History of ear, nose and throat (ENT) disease, e.g. Meniere's disease~* Current treatment with propranolol or medications that would preclude use of a triptan(e.g. ergotamine)~* Major vestibular abnormality found on screening~* Testing positive on over-the-counter pregnancy test~* Taken an Monamine Oxidase (MAO) inhibitor within two weeks of testing~* Allergy or intolerance to gelatin~* Corrected visual acuity of \> 20/40 O.U.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- With Vertigo; Placebo - Rizatriptan (Type: OTHER): This group received placebo on visit 1 and Rizatriptan on visit 2.
- With Vertigo; Rizatriptan - Placebo (Type: OTHER): These subjects received Rizatriptan on visit 1 and placebo on visit 2.
- Without Vertigo; Placebo - Rizatriptan (Type: OTHER): This group received placebo on visit 1 and Rizatriptan on visit 2.
- Without Vertigo; Rizatriptan-Placebo (Type: OTHER): This group received Rizatriptan on visit 1 and placebo on visit 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving cyclosporine (CsA) or tacrolimus (TAC) since the first month post-transplant.~* In addition to a calcineurin inhibitor (CNI), subjects must be treated with either corticosteroids at a dosage range of 2.5 to 15 mg/day for prednisone or prednisolone (2 to 12mg/day for methylprednisolone or the alternate day equivalent) or a steroid-free regimen for a minimum of 12 weeks before randomization or either MMF (\>/=500mg/day), mycophenolate sodium (MPS) (\>/=360 mg/day) or AZA (\>/=50mg/day). Subjects must be taking a minimum of 2 immunosuppressive drugs if on a steroid-free regimen.~* Subject is 3 to 60 months after renal transplantation.~* Subject is greater than 12 weeks after treatment for any acute rejection.~Exclusion Criteria:~* Subjects who are currently receiving, or have received within 4 weeks before enrollment, RAAS blockade.~* Subjects with a calculated GFR \< 40mL/min (per the Modification of Diet in Renal Disease \[MDRD-7\] or abbreviated MDRD formula).~* Subjects with a urine protein to creatinine ratio (U p/c) of \>0.3.~* Subjects with a history of uncontrolled systolic blood pressure (SBP \>140 mm Hg).~* Subjects with severe hepatic impairment (Grade C Child-Pugh score). Additional Inclusion / Exclusion Criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Capsule - initial treatment is 5 mg (active)- oral - once per day
- B (Type: PLACEBO_COMPARATOR): Capsule - initial treatment is 5 mg (placebo) - oral - once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Influenza in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients ≥ 18 years old,~* patients diagnosed with influenza or influenza-like illness caused by a different type of virus,~* patients to whom anti-flu treatment administered,~* patients who have signed informed consent for management of their personal data.~Exclusion Criteria:~* no exclusion criteria except participating in a current clinical trial because of non-interventional sudy design

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Therapy with interferons' inducers (Type: None): Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
- Therapy without interferons' inducers (Type: None): Therapy according to routine practice Groups will be splitted during the final data analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Soy Isoflavones and Breast Cancer Risk Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy premenopausal women~* 30 to 42 years old~* normal mammograms~* regular menstrual cycles~Exclusion Criteria:~* abnormal mammograms~* first degree relatives with breast cancer~* pregnant or lactating~* peri- or post-menopause~* breast augmentation, reduction or lifting~* on oral contraceptive medications or exogenous hormones~* medically prescribed diets~* allergic reaction to soy products

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): soy isoflavones
- 2 (Type: PLACEBO_COMPARATOR): carbohydrates (maltodextrin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HR+/HER2- status after MBC diagnosis.~* Received palbociclib + AI or AI as first-line therapy~Exclusion Criteria:~* Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC~* First structured activity greater than 90 days after MBC diagnostic date~* Treatment with a CDK4/6 inhibitor as part of a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + an aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
- Aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can Mental Health Chatbots Help Chronic Disease Populations?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have a diagnosis of diabetes (type 1 or type 2 diabetes) or arthritis (osteoarthritis, rheumatoid arthritis, or another type of arthritis).~* Participants must have a phone with an active Internet connection.~Exclusion Criteria:~* Participants must not be receiving ongoing treatment from a mental health professional.~* Participants must not be using a mental health chatbot (i.e., prior to the study).~* Participants must not have started or experienced a dosage change in a psychopharmacological drug within the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Wysa) (Type: EXPERIMENTAL): None
- Control Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with PMS for at least 1 year.~* Ages 18-45 years~* Regular menstrual cycles in normal range (22-36 days) for at least 6 months~* In general good health as determined by physical examination and blood tests.~* Evidence of ovulation using a urine test.~* Meeting stated criteria for PMS.~* Signed informed consent.~Exclusion Criteria:~* Any prescription, over-the-counter, herbal or non-medical therapies for PMS.~* Use of psychotropic medications that cannot be stopped for the duration of the study.~* Other current psychiatric diagnoses as determined by SCID interview.~* Alcohol or substance abuse/dependence or suicide attempt within the past 12 months; lifetime history of psychosis, bipolar disorder and clearly identifiable severe personality disorder.~* Hysterectomy, symptomatic endometriosis, irregular menstrual cycles,any severe or unstable medical illness.~* Lack of medically-approved contraception, currently pregnant, intention to become pregnant or breast feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic (Stage IV) or recurrent non-squamous non-small cell lung cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of the disease (Stage IIIb, IV or recurrent disease)~* Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component~* Evidence of tumor invading major blood vessels on imaging~* Central nervous system (CNS) metastases, even if previously treated~* History of hemoptysis in the 3 months prior to enrollment~* History or evidence of inherited bleeding diathesis or coagulopathy~* Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive encephalopathy~* Clinically significant cardiovascular or vascular disease~* Malignancies other than non-small cell lung cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ treated surgically with curative intent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Paclitaxel/Carboplatin (Type: EXPERIMENTAL): Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
- Placebo + Paclitaxel/Carboplatin (Type: ACTIVE_COMPARATOR): Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1 age of 18 to 65 yr,~* 2 body mass index 18.5 to 25.0 kg/m2,~* 3 American Society of Anesthesiologists physical status I to III~* 4 scheduled for elective surgery with an expected duration of at least 60min under general anesthesia with intubation of the trachea or laryngeal mask~* 5 patients having given informed consent to the study~Exclusion Criteria:~* 1 patients who had participated in another clinical trial within 1 month~* 2 Patients with suspected difficult airway, bronchial asthma, chronic obstructive pulmonary disease~* 3 known neuromuscular disease~* 4 suspected malignant hyperthermia~* 5 hepatic or renal dysfunction~* 6 glaucoma~* 7 allergy to the medication that used in this trial~* 8 taking medicaments that might influence the effect of NMB agents~* 9 pregnant, or breastfeeding state~* 10 taking medication known to alter the effect of neuromuscular blocking agents( toremifene .etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sugammadex 0.125 (Type: None): Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 0.25 (Type: None): Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 0.5 (Type: None): Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 1.0 (Type: None): Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
- Sugammadex 2.0 (Type: None): Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 10 (Type: None): Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 25 (Type: None): Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 40 (Type: None): Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 55 (Type: None): Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
- Neostigmine 70 (Type: None): Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
- Placebo (Type: None): Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a premenopausal female at the time of Screening.~* Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound (transabdominal ultrasound/transvaginal ultrasound).~* Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by menstrual blood loss \> 80 mL during each of two screening menses as measured by the alkaline hematin method.~* Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.~* Subject has an adequate endometrial biopsy performed during Screening, the results of which show no clinically significant endometrial pathology.~Exclusion Criteria:~* Subject has screening pelvic ultrasound or saline infusion sonohysterography results that show a clinically significant gynecological disorder.~* Subject has history of osteoporosis or other metabolic bone disease.~* Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.~* Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).~* Subject is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
- Elagolix (Type: EXPERIMENTAL): Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
- Elagolix + E2/NETA (Type: EXPERIMENTAL): Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication~* Body mass index (BMI) 17 to 40 kg/ m2 inclusive~* Subjects with an HbA1c between 7.0% and 10.0% at Screening~* Creatinine clearance \>30 mL/min (calculated using the Cockcroft-Gault formula)~Exclusion Criteria:~* History of type 1 diabetes mellitus~* Female subject is pregnant, lactating, or \<6 weeks postpartum~* Clinically significant cardiovascular and/or cerebrovascular disease~* Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator~* Serum amylase \>=3 ×ULN and/or serum lipase \>=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis~* Prior use of a GLP-1R agonist or DPP-IV inhibitor within 6 months before Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albiglutide + Sulfonylurea (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background sulfonylurea
- Albiglutide + Biguanide (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background biguanide
- Albiglutide + Glinide (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background glinide
- Albiglutide + Thiazolidinedione (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background thiazolidinedione
- Albiglutide + Alpha-glucosidase inhibitor (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background alpha-glucosidase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete